ReviewInternational journal of molecular medicine2017
Human osteopontin: Potential clinical applications in cancer (Review).
Review in International journal of molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Applications of Bacterial Cellulose-Based Composite Materials in Hard Tissue Regenerative Medicine.Tissue engineering and regenerative medicine · 2023Pooled it
- Preliminary study on the mechanism of OPN up-regulating PD-L1 to induce CD8 + T cell exhaustion in synovial sarcoma.BMC cancer · 2026Article
- PCOS and breast cancer risk: hormonal modulation and epidemiological trends.Reproductive health · 2026Review
- Osteopontin-4 (OPN-4) Suppresses Tumor Progression Features Whilst Sensitizing c643 Anaplastic Thyroid Cells to Sorafenib.Biomedicines · 2026Article
- Colorectal cancer-derived osteopontin rewires macrophages into a pro-metastatic M2 state via the PI3K/AKT/CSF1-CSF1R axis.Cell death discovery · 2026Article
- SPP1 promotes cancer stemness and reduces osimertinib sensitivity in non-small cell lung cancer through interactions with CD44.Cancer cell international · 2026Article
- The role of SPP1 in evaluating the prognosis, immune infiltration, and drug sensitivity of hepatocellular carcinoma.PloS one · 2026Article
- Role of osteopontin in cancer: From pathogenesis to therapeutics (Review).Oncology reports · 2025Review
- CD44 Participates to Extramedullary Haematopoiesis Onset by Mediating the Interplay Between Monocytes and Haematopoietic Stem Cells in Myelofibrosis.Journal of cellular and molecular medicine · 2025Article
- SPP1 induces idiopathic pulmonary fibrosis and NSCLC progression via the PI3K/Akt/mTOR pathway.Respiratory research · 2024Article
- Osteopontin: an essential regulatory protein in idiopathic pulmonary fibrosis.Journal of molecular histology · 2024Review
- SPP1 mRNA determination based on molecular beacon for the recurrence prognosis of bladder cancer.Translational andrology and urology · 2023Article
- Entrectinib a Plausible Inhibitor for Osteopontin (SPP1) in Cervical Cancer-Integrated Bioinformatic Approach.Applied biochemistry and biotechnology · 2023Article
- Osteopontin is a prognostic circulating biomarker in patients with neuroendocrine neoplasms.Journal of cancer research and clinical oncology · 2023Article
- Article
- What is new in cancer-associated fibroblast biomarkers?Cell communication and signaling : CCS · 2023Review
- Increased Circulating Osteopontin Levels Promote Primary Tumour Growth, but Do Not Induce Metastasis in Melanoma.Biomedicines · 2023Article
- Intrahepatic Cholangiocarcinoma Developing in Patients with Metabolic Syndrome Is Characterized by Osteopontin Overexpression in the Tumor Stroma.International journal of molecular sciences · 2023Article
- The Intracellular and Secreted Sides of Osteopontin and Their Putative Physiopathological Roles.International journal of molecular sciences · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human osteopontin (OPN) is a glycosylated phosphoprotein which is expressed in a variety of tissues in the body. In recent years, accumulating evidence has indicated that the aberrant expression of OPN is closely associated with tumourigensis, progression and most prominently with metastasis in several tumour types. In this review, we present the current knowledge on the expression profiles of OPN and its main splice variants in human cancers, as well as the potential implications in patient outcome. We also discuss its putative clinical application as a cancer biomarker and as a therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.